These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
58 related articles for article (PubMed ID: 18936110)
1. Discovering plausible mechanistic details of hepatic drug interactions. Lam TN; Hunt CA Drug Metab Dispos; 2009 Jan; 37(1):237-46. PubMed ID: 18936110 [TBL] [Abstract][Full Text] [Related]
2. Mechanistic insight from in silico pharmacokinetic experiments: roles of P-glycoprotein, Cyp3A4 enzymes, and microenvironments. Lam TN; Hunt CA J Pharmacol Exp Ther; 2010 Feb; 332(2):398-412. PubMed ID: 19864617 [TBL] [Abstract][Full Text] [Related]
3. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. Lau YY; Wu CY; Okochi H; Benet LZ J Pharmacol Exp Ther; 2004 Mar; 308(3):1040-5. PubMed ID: 14634033 [TBL] [Abstract][Full Text] [Related]
4. In silico methods for unraveling the mechanistic complexities of intestinal absorption: metabolism-efflux transport interactions. Garmire LX; Hunt CA Drug Metab Dispos; 2008 Jul; 36(7):1414-24. PubMed ID: 18436618 [TBL] [Abstract][Full Text] [Related]
5. Predictions of hepatic disposition properties using a mechanistically realistic, physiologically based model. Yan L; Sheihk-Bahaei S; Park S; Ropella GE; Hunt CA Drug Metab Dispos; 2008 Apr; 36(4):759-68. PubMed ID: 18227144 [TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of saturable hepatic uptake of digoxin and its inhibition by rifampicin. Weiss M; Hung DY; Poenicke K; Roberts MS Eur J Pharm Sci; 2008 Aug; 34(4-5):345-50. PubMed ID: 18573335 [TBL] [Abstract][Full Text] [Related]
7. Computational strategies unravel and trace how liver disease changes hepatic drug disposition. Park S; Ropella GE; Kim SH; Roberts MS; Hunt CA J Pharmacol Exp Ther; 2009 Jan; 328(1):294-305. PubMed ID: 18948498 [TBL] [Abstract][Full Text] [Related]
8. Tracing multiscale mechanisms of drug disposition in normal and diseased livers. Park S; Kim SH; Ropella GE; Roberts MS; Hunt CA J Pharmacol Exp Ther; 2010 Jul; 334(1):124-36. PubMed ID: 20406856 [TBL] [Abstract][Full Text] [Related]
9. Modeling and simulation of hepatic drug disposition using a physiologically based, multi-agent in silico liver. Yan L; Ropella GE; Park S; Roberts MS; Hunt CA Pharm Res; 2008 May; 25(5):1023-36. PubMed ID: 18044012 [TBL] [Abstract][Full Text] [Related]
10. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I). Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574 [TBL] [Abstract][Full Text] [Related]
11. Silibinin protects OTA-mediated TNF-alpha release from perfused rat livers and isolated rat Kupffer cells. Al-Anati L; Essid E; Reinehr R; Petzinger E Mol Nutr Food Res; 2009 Apr; 53(4):460-6. PubMed ID: 19156713 [TBL] [Abstract][Full Text] [Related]
12. Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats. Shitara Y; Nagamatsu Y; Wada S; Sugiyama Y; Horie T Drug Metab Dispos; 2009 Jun; 37(6):1172-8. PubMed ID: 19282398 [TBL] [Abstract][Full Text] [Related]
13. Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver. Turkanovic J; Ngo SN; Milne RW J Pharm Pharmacol; 2009 Aug; 61(8):1037-42. PubMed ID: 19703347 [TBL] [Abstract][Full Text] [Related]
15. [Quantitative approach for calculation of pharmacodynamic interactions and simulation of combined response]. Chen JC; Pan YJ; Li XS; Sun J; Liu HX; Sun RY; Zheng QS Zhongguo Zhong Yao Za Zhi; 2008 Aug; 33(16):2029-33. PubMed ID: 19086647 [TBL] [Abstract][Full Text] [Related]
16. Limited sampling strategy in rats to predict the inhibited activities of hepatic CYP3A. Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX Lab Anim; 2009 Jul; 43(3):284-90. PubMed ID: 19237454 [TBL] [Abstract][Full Text] [Related]
17. Using an in silico liver to evaluate a hepatic enzyme induction mechanism. Hunt C; Ropella GE Annu Int Conf IEEE Eng Med Biol Soc; 2008; 2008():2415-8. PubMed ID: 19163189 [TBL] [Abstract][Full Text] [Related]
18. Pretreatment with calcitonin gene-related peptide attenuates hepatic ischemia/reperfusion injury in rats. Song SW; Guo KJ; Shi R; Cheng Y; Liu YF Transplant Proc; 2009 Jun; 41(5):1493-8. PubMed ID: 19545664 [TBL] [Abstract][Full Text] [Related]
19. In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. Thelingwani RS; Zvada SP; Dolgos H; Ungell AL; Masimirembwa CM Drug Metab Dispos; 2009 Jun; 37(6):1286-94. PubMed ID: 19299526 [TBL] [Abstract][Full Text] [Related]
20. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality. Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]